Levels of soluble Fas/APO-1 in patients with Behçet's disease
The aim of this study was to quantify soluble Fas/APO1 (sFas/APO-1) protein in the serum of patients with Behcet's disease (BD) in active and inactive stages, compared with patients with systemic lupus erythematosus (SLE) and patients with rheumatoid arthritis (RA). Soluble Fas/APO-1 was quanti...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1998-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1080/09629359891261 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841524530782142464 |
|---|---|
| author | K. Hamzaoui A. Hamzaoui L. Zakraoui A. Chabbou |
| author_facet | K. Hamzaoui A. Hamzaoui L. Zakraoui A. Chabbou |
| author_sort | K. Hamzaoui |
| collection | DOAJ |
| description | The aim of this study was to quantify soluble Fas/APO1 (sFas/APO-1) protein in the serum of patients with Behcet's disease (BD) in active and inactive stages, compared with patients with systemic lupus erythematosus (SLE) and patients with rheumatoid arthritis (RA). Soluble Fas/APO-1 was quantified using a sandwich enzyme-linked immunosorbent assay. Increased serum sFas/APO-1 levels were observed in active BD, compared with inactive BD, RA patients and SLE patients. Increased serum sFas/APO-1 levels were correlated with the presence of neurologic manifestations or pulmonary involvement in active BD. In conclusion, increased levels of sFas/APO-1 occurred frequently and exclusively in active BD patients. Preliminary evidence suggested that elevated levels of sFas/APO-1 are associated with the clinical stage and clinical manifestations in BD. |
| format | Article |
| id | doaj-art-39b9478363f04ba3a8fdf59b227d3164 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 1998-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-39b9478363f04ba3a8fdf59b227d31642025-02-03T05:52:54ZengWileyMediators of Inflammation0962-93511466-18611998-01-017211111410.1080/09629359891261Levels of soluble Fas/APO-1 in patients with Behçet's diseaseK. Hamzaoui0A. Hamzaoui1L. Zakraoui2A. Chabbou3Immunohistology Laboratory, Medicine University of Tunis, Pavillon VI, 9 rue Dr Z. Essafi , Tunis 1007, TunisiaDepartment of Respiratory Diseases, Pav II, Ariana, TunisiaDepartment of Rheumatology, Marsa Hospital, TunisiaDepartment of Respiratory Diseases, Pav II, Ariana, TunisiaThe aim of this study was to quantify soluble Fas/APO1 (sFas/APO-1) protein in the serum of patients with Behcet's disease (BD) in active and inactive stages, compared with patients with systemic lupus erythematosus (SLE) and patients with rheumatoid arthritis (RA). Soluble Fas/APO-1 was quantified using a sandwich enzyme-linked immunosorbent assay. Increased serum sFas/APO-1 levels were observed in active BD, compared with inactive BD, RA patients and SLE patients. Increased serum sFas/APO-1 levels were correlated with the presence of neurologic manifestations or pulmonary involvement in active BD. In conclusion, increased levels of sFas/APO-1 occurred frequently and exclusively in active BD patients. Preliminary evidence suggested that elevated levels of sFas/APO-1 are associated with the clinical stage and clinical manifestations in BD.http://dx.doi.org/10.1080/09629359891261 |
| spellingShingle | K. Hamzaoui A. Hamzaoui L. Zakraoui A. Chabbou Levels of soluble Fas/APO-1 in patients with Behçet's disease Mediators of Inflammation |
| title | Levels of soluble Fas/APO-1 in patients with Behçet's disease |
| title_full | Levels of soluble Fas/APO-1 in patients with Behçet's disease |
| title_fullStr | Levels of soluble Fas/APO-1 in patients with Behçet's disease |
| title_full_unstemmed | Levels of soluble Fas/APO-1 in patients with Behçet's disease |
| title_short | Levels of soluble Fas/APO-1 in patients with Behçet's disease |
| title_sort | levels of soluble fas apo 1 in patients with behcet s disease |
| url | http://dx.doi.org/10.1080/09629359891261 |
| work_keys_str_mv | AT khamzaoui levelsofsolublefasapo1inpatientswithbehcetsdisease AT ahamzaoui levelsofsolublefasapo1inpatientswithbehcetsdisease AT lzakraoui levelsofsolublefasapo1inpatientswithbehcetsdisease AT achabbou levelsofsolublefasapo1inpatientswithbehcetsdisease |